Biomarker testing, which is testing to identify changes in the cells that are “driving” the cancer to grow and spread, is vital to understanding treatment options for people diagnosed with non-small cell lung cancer. The results of biomarker testing can show if targeted therapies or immunotherapies should be included in treatment options.
The worldwide lung cancer advocacy community now consists of numerous groups with differing aims, objectives, and agendas. GLCC has created this resource of groups dedicated to specific biomarkers to help meet the specialized interests of people diagnosed whose cancer has specific, targetable biomarkers.
We aim to maintain a complete list, so if you are aware of a group we’ve missed, please contact us via: glcc@roycastle.org
